Tomas Odergren
Hoofd Techniek/Wetenschap/O&O bij BIOARCTIC AB
Vermogen: 101 267 $ op 30-04-2024
Momenteel actieve connecties
Naam | Geslacht | Leeftijd | Verwante bedrijven | Samenwerking |
---|---|---|---|---|
Pär Lars Gellerfors | M | 77 | 21 jaar | |
Lars Gunnar Lannfelt | M | 75 | 21 jaar | |
Eugen Steiner | M | 70 | 7 jaar | |
Åke Mikael Smedeby | M | 56 | 6 jaar | |
Charlotta Ljungqvist | M | 63 | 3 jaar | |
Oskar Bosson | M | 48 | 4 jaar | |
Jan Mattsson | M | 64 | 7 jaar | |
Gunilla Christina Osswald | M | 63 | 11 jaar | |
Cecilia Marie Edström | F | 58 | 1 jaar | |
Gunilla Anders Ekström | M | 66 |
NovaSAID AB
NovaSAID AB Pharmaceuticals: MajorHealth Technology NovaSAID AB develops treatments for inflammation and pain in conditions such as rheumatoid arthritis. It discovers selective microsomal prostaglandin E synthase-1 (mPGES-1), and has also demonstrated its effect in animal models for pain and inflammation. The firm's approach is to prevent the pathological formation of prostaglandin E2 (PGE2) selectively, through the development of inhibitors of mPGES-1, the enzyme that is responsible for the formation of PGE2 during inflammation. Its mPGES-1 inhibition offers an approach for inhibiting pathological PGE2 production without adversely affecting other important prostanoids. The company was founded by Per-Johan Göte Jakobsson, Ralf Morgenstern, Bertil Samuelsson and Bengt Ingemar Samuelsson on October 26, 2004 and is headquartered in Solna, Sweden. | - |
Christer Möller | M | 65 | 18 jaar | |
Anders Martin-Löf | M | 53 | 1 jaar | |
Carl Jonas Stefan Ståhlberg | M | 49 |
NovaSAID AB
NovaSAID AB Pharmaceuticals: MajorHealth Technology NovaSAID AB develops treatments for inflammation and pain in conditions such as rheumatoid arthritis. It discovers selective microsomal prostaglandin E synthase-1 (mPGES-1), and has also demonstrated its effect in animal models for pain and inflammation. The firm's approach is to prevent the pathological formation of prostaglandin E2 (PGE2) selectively, through the development of inhibitors of mPGES-1, the enzyme that is responsible for the formation of PGE2 during inflammation. Its mPGES-1 inhibition offers an approach for inhibiting pathological PGE2 production without adversely affecting other important prostanoids. The company was founded by Per-Johan Göte Jakobsson, Ralf Morgenstern, Bertil Samuelsson and Bengt Ingemar Samuelsson on October 26, 2004 and is headquartered in Solna, Sweden. | - |
Johanna Fälting | M | 52 | 12 jaar | |
Gunilla Andersson | F | 63 | 5 jaar | |
Anna-Kaija Grönblad | F | 56 | 3 jaar |
Relatiegrafiek
Connectie in verschillende bedrijven
Oude connecties
Naam | Geslacht | Leeftijd | Verwante bedrijven | Samenwerking |
---|---|---|---|---|
Wenche Nelly A. Rolfsen Sandsborg | M | 72 | 7 jaar | |
Hans Christian Ekelund | M | 76 | 7 jaar | |
Bengt Håkan Englund | M | 72 | 4 jaar | |
Klaus K. Wilgenbus | M | 62 | 2 jaar | |
Rune Fransson | M | 77 | 8 jaar | |
Henrijette Richter | M | 53 | 3 jaar | |
Lennart Rolf Ivar Verner | M | 77 | 14 jaar | |
Per-Olof Edin | M | 84 | 7 jaar | |
Carl Johan Bertil Sundberg | M | 66 | 3 jaar | |
Bo Jesper Hansen | M | 66 | 4 jaar | |
Bruno Lucidi | M | 64 | - | |
Torbjørn Bjerke | M | 61 | 3 jaar | |
Christian Henrik Tange | M | 58 | 3 jaar | |
Stig Michael Sundström | M | 61 | 3 jaar | |
Hans Uno Postlind | M | 63 | - | |
Robert Leslie Holland | M | 69 | - | |
Christine Lind | F | 50 | - | |
Ewa Björling | M | 63 | 1 jaar | |
Nora Sjödin | F | 67 | 3 jaar |
Statistieken
Land | Connecties | % van het totaal |
---|---|---|
Zweden | 35 | 100.00% |
Ouderdom van de connecties
Actief
Verleden
Man
Vrouw
Besturend
Uitvoerend
Oorsprong van de connecties
- Beurs
- Insiders
- Tomas Odergren
- Persoonlijk netwerk